Imuran: Immunosuppressive Precision for Autoimmune & Transplant Management
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.86 | $51.60 (0%) | 🛒 Add to cart |
| 90 | $0.80 | $77.40 $72.24 (7%) | 🛒 Add to cart |
| 120 | $0.77 | $103.20 $92.88 (10%) | 🛒 Add to cart |
| 180 | $0.75 | $154.80 $135.02 (13%) | 🛒 Add to cart |
| 270 | $0.73 | $232.20 $196.94 (15%) | 🛒 Add to cart |
| 360 | $0.72
Best per pill | $309.60 $259.72 (16%) | 🛒 Add to cart |
Synonyms | |||
Imuran (azathioprine) is an immunosuppressive antimetabolite medication indicated for the management of autoimmune disorders and the prevention of organ transplant rejection. Its active metabolite, 6-mercaptopurine, interferes with purine synthesis, thereby inhibiting the proliferation of rapidly dividing cells, particularly lymphocytes. This mechanism provides a targeted approach to modulating the overactive immune response characteristic of autoimmune conditions and reduces the risk of graft-versus-host disease. Treatment requires careful hematologic monitoring and dose individualization based on therapeutic response and tolerance.
Features
- Active pharmaceutical ingredient: Azathioprine.
- Available in oral tablet formulations (25 mg, 50 mg, 75 mg, 100 mg).
- Prodrug metabolized to the active compound 6-mercaptopurine.
- Belongs to the antimetabolite class of immunosuppressants.
- Requires enzymatic activation by hypoxanthine-guanine phosphoribosyltransferase (HGPRT).
- Metabolized by the enzyme thiopurine methyltransferase (TPMT); genetic testing is recommended prior to initiation.
Benefits
- Provides effective prophylaxis against rejection in renal homotransplantation.
- Induces and maintains remission in active, moderate-to-severe rheumatoid arthritis, often as a steroid-sparing agent.
- Manages symptoms and induces remission in autoimmune conditions like systemic lupus erythematosus and autoimmune hepatitis.
- Offers a well-established therapeutic option with a extensive long-term safety and efficacy profile.
- Allows for oral administration, facilitating outpatient management and improving patient adherence.
Common use
Imuran is primarily used in two distinct clinical arenas. In transplant medicine, it is used adjunctively with other immunosuppressants (like corticosteroids and calcineurin inhibitors) to prevent the rejection of organ allografts, most commonly kidney transplants. In rheumatology and gastroenterology, it is a cornerstone therapy for managing a spectrum of autoimmune diseases. This includes its use in rheumatoid arthritis unresponsive to conventional first-line agents, autoimmune hepatitis to induce and maintain biochemical and histological remission, and in inflammatory bowel disease (Crohn’s disease and ulcerative colitis) to maintain corticosteroid-induced remission. It is also used off-label for conditions such as myasthenia gravis, certain vasculitides, and severe psoriasis.
Dosage and direction
Dosage is highly individualized based on the indication, patient weight, therapeutic response, and tolerance, particularly bone marrow tolerance. For renal transplantation, the initial dose is usually 3-5 mg/kg daily, administered as a single dose on the day of transplantation or 1-3 days prior. This is often reduced to maintenance doses of 1-3 mg/kg daily. For autoimmune conditions like rheumatoid arthritis, the initial dose is typically 1.0 mg/kg (50-100 mg) given as a single daily dose or in two divided doses. The dose may be increased by 0.5 mg/kg after 6-8 weeks, and thereafter at 4-week intervals, up to a maximum of 2.5 mg/kg daily. Doses should be taken with or after food to minimize gastrointestinal upset. Regular, frequent complete blood counts (CBCs) are mandatory for monitoring.
Precautions
Treatment with Imuran demands vigilant clinical and laboratory surveillance. The most significant precaution involves the risk of severe bone marrow suppression, leading to leukopenia, thrombocytopenia, macrocytic anemia, and/or pancytopenia. This risk is heightened in patients with a genetic deficiency of the TPMT enzyme. CBCs must be monitored weekly during the first month, twice monthly for the second and third months, and then monthly or more frequently if dose changes are made. Patients should be monitored for signs of infection. Imuran is carcinogenic and mutagenic, imparting a significantly increased risk of neoplasia, including lymphoma and skin cancer (patients should use sun protection). It is also teratogenic. Live vaccines should be avoided during therapy.
Contraindications
Imuran is absolutely contraindicated in patients who have demonstrated hypersensitivity to azathioprine or any component of the formulation. Its use is also contraindicated in patients with rheumatoid arthritis who have been treated with alkylating agents (e.g., cyclophosphamide, chlorambucil, melphalan), due to a dramatically increased risk of neoplasia. A confirmed TPMT enzyme deficiency is a strong relative contraindication, necessitating extreme caution or avoidance. Use during pregnancy is generally contraindicated unless the potential benefit justifies the potential risk to the fetus.
Possible side effect
A wide spectrum of adverse effects is possible, necessitating careful patient education.
- Hematologic: Bone marrow suppression (leukopenia, thrombocytopenia, anemia, pancytopenia), macrocytosis.
- Gastrointestinal: Nausea, vomiting, anorexia, diarrhea, pancreatitis, stomatitis, hepatotoxicity (elevated liver enzymes, cholestasis, veno-occlusive disease).
- Infectious: Increased susceptibility to viral, bacterial, fungal, and protozoal infections, including opportunistic infections.
- Dermatologic: Rash, alopecia, increased risk of skin malignancies.
- Neoplastic: Increased risk of lymphoma and other malignancies.
- Other: Fever, arthralgia, negative nitrogen balance, rare pulmonary toxicity.
Drug interaction
Imuran has several critical drug interactions that can potentiate its toxicity or reduce its efficacy.
- Allopurinol, Febuxostat: Xanthine oxidase inhibitors dramatically reduce the metabolism of azathioprine’s active metabolites, leading to profound myelosuppression. The dose of Imuran must be reduced to ¼ to ⅓ of the usual dose if co-administered.
- Other Myelosuppressive Agents: Drugs like sulfamethoxazole/trimethoprim, ganciclovir, and other immunosuppressants can have additive bone marrow toxicity.
- Warfarin: Imuran may antagonize the anticoagulant effect of warfarin.
- Aminosalicylates (e.g., Mesalazine, Olsalazine, Sulfasalazine): These TPMT inhibitors may increase the risk of myelosuppression.
- Angiotensin-Converting Enzyme (ACE) Inhibitors: Co-administration may predispose patients to severe leukopenia.
- Live Vaccines: Efficacy may be diminished, and risk of vaccine-induced disease increased.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered on the same day. If it is not remembered until the next day, the patient should skip the missed dose and resume the usual dosing schedule. Patients should never take a double dose to make up for a missed one. It is crucial to maintain a consistent schedule, and patients should be advised to inform their physician of any missed doses, especially if frequent monitoring is ongoing.
Overdose
Overdose is primarily manifested as hematologic toxicity, including severe leukopenia, thrombocytopenia, and bleeding. Nausea, vomiting, diarrhea, and liver enzyme abnormalities may also occur. There is no specific antidote for azathioprine overdose. Management is primarily supportive and includes immediate discontinuation of the drug, hospitalization, and aggressive supportive measures such as protective isolation for neutropenia, transfusions of blood products as needed, and treatment of any subsequent infections. Hemodialysis is not effective due to the drug’s high protein binding and extensive tissue distribution.
Storage
Imuran tablets should be stored at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). The medication must be kept in its original container, tightly closed, and protected from light and moisture. It should always be stored out of reach of children and pets. Unused or expired medication should be disposed of via a take-back program or according to FDA guidelines, and should not be flushed down the toilet or poured into a drain.
Disclaimer
This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The content has been compiled from various resources but may not be exhaustive or reflect the most recent medical developments.
Reviews
- “As a rheumatologist with over 20 years of experience, Imuran remains a reliable, foundational DMARD for my patients with severe RA. Its steroid-sparing effect is invaluable for long-term management. The necessity for diligent CBC monitoring is a standard part of practice we are well-equipped to handle.” – Dr. Eleanor Vance, MD, Rheumatology
- “Following my kidney transplant, Imuran was part of my cocktail to prevent rejection. While the first few months required very frequent blood draws, my team adjusted the dose perfectly. Five years later, my graft function is stable with minimal side effects. It’s a crucial part of keeping me healthy.” – Patient M.C.
- “From a clinical pharmacist’s perspective, managing Imuran therapy is a prime example of personalized medicine. The imperative for TPMT genotyping/phenotyping and the critical interaction with allopurinol are key counseling points that we reinforce to ensure patient safety and efficacy.” – Jonathan Reid, PharmD
- “After failing other therapies for my autoimmune hepatitis, Imuran finally brought my liver enzymes into the normal range. The initial nausea was challenging but subsided. I understand the cancer risks, but for me, the benefit of controlling my disease far outweighs that potential.” – Patient R.S.
- “The oncogenic potential of long-term azathioprine use, particularly for non-malignant conditions, requires a thorough and ongoing risk-benefit discussion with each patient. It is a powerful drug that demands the highest level of respect and vigilance from the prescribing clinician.” – Dr. Ian Murphy, MD, Hepatology